Global Biosimilar Insulin Glargine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 97

Published Date: 09 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

According to our (Global Info Research) latest study, the global Biosimilar Insulin Glargine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Biosimilar Insulin Glargine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Biosimilar Insulin Glargine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Biosimilar Insulin Glargine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Biosimilar Insulin Glargine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Biosimilar Insulin Glargine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosimilar Insulin Glargine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosimilar Insulin Glargine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Gan&Lee, Tonghua Dongbao, United Laboratory and Geropharm, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation
Biosimilar Insulin Glargine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Pre-filled
    Cartridge

Market segment by Application
    Hospital
    Retail Pharmacy
    Others

Major players covered
    Eli Lilly
    Gan&Lee
    Tonghua Dongbao
    United Laboratory
    Geropharm
    Biocon
    Wockhardt

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilar Insulin Glargine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilar Insulin Glargine, with price, sales, revenue and global market share of Biosimilar Insulin Glargine from 2018 to 2023.
Chapter 3, the Biosimilar Insulin Glargine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Insulin Glargine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Biosimilar Insulin Glargine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Insulin Glargine.
Chapter 14 and 15, to describe Biosimilar Insulin Glargine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Biosimilar Insulin Glargine
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Biosimilar Insulin Glargine Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Pre-filled
        1.3.3 Cartridge
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Biosimilar Insulin Glargine Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital
        1.4.3 Retail Pharmacy
        1.4.4 Others
    1.5 Global Biosimilar Insulin Glargine Market Size & Forecast
        1.5.1 Global Biosimilar Insulin Glargine Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Biosimilar Insulin Glargine Sales Quantity (2018-2029)
        1.5.3 Global Biosimilar Insulin Glargine Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 Eli Lilly
        2.1.1 Eli Lilly Details
        2.1.2 Eli Lilly Major Business
        2.1.3 Eli Lilly Biosimilar Insulin Glargine Product and Services
        2.1.4 Eli Lilly Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Eli Lilly Recent Developments/Updates
    2.2 Gan&Lee
        2.2.1 Gan&Lee Details
        2.2.2 Gan&Lee Major Business
        2.2.3 Gan&Lee Biosimilar Insulin Glargine Product and Services
        2.2.4 Gan&Lee Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Gan&Lee Recent Developments/Updates
    2.3 Tonghua Dongbao
        2.3.1 Tonghua Dongbao Details
        2.3.2 Tonghua Dongbao Major Business
        2.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Product and Services
        2.3.4 Tonghua Dongbao Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Tonghua Dongbao Recent Developments/Updates
    2.4 United Laboratory
        2.4.1 United Laboratory Details
        2.4.2 United Laboratory Major Business
        2.4.3 United Laboratory Biosimilar Insulin Glargine Product and Services
        2.4.4 United Laboratory Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 United Laboratory Recent Developments/Updates
    2.5 Geropharm
        2.5.1 Geropharm Details
        2.5.2 Geropharm Major Business
        2.5.3 Geropharm Biosimilar Insulin Glargine Product and Services
        2.5.4 Geropharm Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Geropharm Recent Developments/Updates
    2.6 Biocon
        2.6.1 Biocon Details
        2.6.2 Biocon Major Business
        2.6.3 Biocon Biosimilar Insulin Glargine Product and Services
        2.6.4 Biocon Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Biocon Recent Developments/Updates
    2.7 Wockhardt
        2.7.1 Wockhardt Details
        2.7.2 Wockhardt Major Business
        2.7.3 Wockhardt Biosimilar Insulin Glargine Product and Services
        2.7.4 Wockhardt Biosimilar Insulin Glargine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Wockhardt Recent Developments/Updates

3 Competitive Environment: Biosimilar Insulin Glargine by Manufacturer
    3.1 Global Biosimilar Insulin Glargine Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Biosimilar Insulin Glargine Revenue by Manufacturer (2018-2023)
    3.3 Global Biosimilar Insulin Glargine Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Biosimilar Insulin Glargine by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Biosimilar Insulin Glargine Manufacturer Market Share in 2022
        3.4.2 Top 6 Biosimilar Insulin Glargine Manufacturer Market Share in 2022
    3.5 Biosimilar Insulin Glargine Market: Overall Company Footprint Analysis
        3.5.1 Biosimilar Insulin Glargine Market: Region Footprint
        3.5.2 Biosimilar Insulin Glargine Market: Company Product Type Footprint
        3.5.3 Biosimilar Insulin Glargine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Biosimilar Insulin Glargine Market Size by Region
        4.1.1 Global Biosimilar Insulin Glargine Sales Quantity by Region (2018-2029)
        4.1.2 Global Biosimilar Insulin Glargine Consumption Value by Region (2018-2029)
        4.1.3 Global Biosimilar Insulin Glargine Average Price by Region (2018-2029)
    4.2 North America Biosimilar Insulin Glargine Consumption Value (2018-2029)
    4.3 Europe Biosimilar Insulin Glargine Consumption Value (2018-2029)
    4.4 Asia-Pacific Biosimilar Insulin Glargine Consumption Value (2018-2029)
    4.5 South America Biosimilar Insulin Glargine Consumption Value (2018-2029)
    4.6 Middle East and Africa Biosimilar Insulin Glargine Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Biosimilar Insulin Glargine Sales Quantity by Type (2018-2029)
    5.2 Global Biosimilar Insulin Glargine Consumption Value by Type (2018-2029)
    5.3 Global Biosimilar Insulin Glargine Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Biosimilar Insulin Glargine Sales Quantity by Application (2018-2029)
    6.2 Global Biosimilar Insulin Glargine Consumption Value by Application (2018-2029)
    6.3 Global Biosimilar Insulin Glargine Average Price by Application (2018-2029)

7 North America
    7.1 North America Biosimilar Insulin Glargine Sales Quantity by Type (2018-2029)
    7.2 North America Biosimilar Insulin Glargine Sales Quantity by Application (2018-2029)
    7.3 North America Biosimilar Insulin Glargine Market Size by Country
        7.3.1 North America Biosimilar Insulin Glargine Sales Quantity by Country (2018-2029)
        7.3.2 North America Biosimilar Insulin Glargine Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Biosimilar Insulin Glargine Sales Quantity by Type (2018-2029)
    8.2 Europe Biosimilar Insulin Glargine Sales Quantity by Application (2018-2029)
    8.3 Europe Biosimilar Insulin Glargine Market Size by Country
        8.3.1 Europe Biosimilar Insulin Glargine Sales Quantity by Country (2018-2029)
        8.3.2 Europe Biosimilar Insulin Glargine Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Biosimilar Insulin Glargine Market Size by Region
        9.3.1 Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Biosimilar Insulin Glargine Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Biosimilar Insulin Glargine Sales Quantity by Type (2018-2029)
    10.2 South America Biosimilar Insulin Glargine Sales Quantity by Application (2018-2029)
    10.3 South America Biosimilar Insulin Glargine Market Size by Country
        10.3.1 South America Biosimilar Insulin Glargine Sales Quantity by Country (2018-2029)
        10.3.2 South America Biosimilar Insulin Glargine Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Biosimilar Insulin Glargine Market Size by Country
        11.3.1 Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Biosimilar Insulin Glargine Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Biosimilar Insulin Glargine Market Drivers
    12.2 Biosimilar Insulin Glargine Market Restraints
    12.3 Biosimilar Insulin Glargine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain
    13.1 Raw Material of Biosimilar Insulin Glargine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Biosimilar Insulin Glargine
    13.3 Biosimilar Insulin Glargine Production Process
    13.4 Biosimilar Insulin Glargine Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Biosimilar Insulin Glargine Typical Distributors
    14.3 Biosimilar Insulin Glargine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Biosimilar Insulin Glargine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Biosimilar Insulin Glargine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
    Table 4. Eli Lilly Major Business
    Table 5. Eli Lilly Biosimilar Insulin Glargine Product and Services
    Table 6. Eli Lilly Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. Eli Lilly Recent Developments/Updates
    Table 8. Gan&Lee Basic Information, Manufacturing Base and Competitors
    Table 9. Gan&Lee Major Business
    Table 10. Gan&Lee Biosimilar Insulin Glargine Product and Services
    Table 11. Gan&Lee Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. Gan&Lee Recent Developments/Updates
    Table 13. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
    Table 14. Tonghua Dongbao Major Business
    Table 15. Tonghua Dongbao Biosimilar Insulin Glargine Product and Services
    Table 16. Tonghua Dongbao Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. Tonghua Dongbao Recent Developments/Updates
    Table 18. United Laboratory Basic Information, Manufacturing Base and Competitors
    Table 19. United Laboratory Major Business
    Table 20. United Laboratory Biosimilar Insulin Glargine Product and Services
    Table 21. United Laboratory Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. United Laboratory Recent Developments/Updates
    Table 23. Geropharm Basic Information, Manufacturing Base and Competitors
    Table 24. Geropharm Major Business
    Table 25. Geropharm Biosimilar Insulin Glargine Product and Services
    Table 26. Geropharm Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Geropharm Recent Developments/Updates
    Table 28. Biocon Basic Information, Manufacturing Base and Competitors
    Table 29. Biocon Major Business
    Table 30. Biocon Biosimilar Insulin Glargine Product and Services
    Table 31. Biocon Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 32. Biocon Recent Developments/Updates
    Table 33. Wockhardt Basic Information, Manufacturing Base and Competitors
    Table 34. Wockhardt Major Business
    Table 35. Wockhardt Biosimilar Insulin Glargine Product and Services
    Table 36. Wockhardt Biosimilar Insulin Glargine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 37. Wockhardt Recent Developments/Updates
    Table 38. Global Biosimilar Insulin Glargine Sales Quantity by Manufacturer (2018-2023) & (K Units)
    Table 39. Global Biosimilar Insulin Glargine Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 40. Global Biosimilar Insulin Glargine Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 41. Market Position of Manufacturers in Biosimilar Insulin Glargine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 42. Head Office and Biosimilar Insulin Glargine Production Site of Key Manufacturer
    Table 43. Biosimilar Insulin Glargine Market: Company Product Type Footprint
    Table 44. Biosimilar Insulin Glargine Market: Company Product Application Footprint
    Table 45. Biosimilar Insulin Glargine New Market Entrants and Barriers to Market Entry
    Table 46. Biosimilar Insulin Glargine Mergers, Acquisition, Agreements, and Collaborations
    Table 47. Global Biosimilar Insulin Glargine Sales Quantity by Region (2018-2023) & (K Units)
    Table 48. Global Biosimilar Insulin Glargine Sales Quantity by Region (2024-2029) & (K Units)
    Table 49. Global Biosimilar Insulin Glargine Consumption Value by Region (2018-2023) & (USD Million)
    Table 50. Global Biosimilar Insulin Glargine Consumption Value by Region (2024-2029) & (USD Million)
    Table 51. Global Biosimilar Insulin Glargine Average Price by Region (2018-2023) & (US$/Unit)
    Table 52. Global Biosimilar Insulin Glargine Average Price by Region (2024-2029) & (US$/Unit)
    Table 53. Global Biosimilar Insulin Glargine Sales Quantity by Type (2018-2023) & (K Units)
    Table 54. Global Biosimilar Insulin Glargine Sales Quantity by Type (2024-2029) & (K Units)
    Table 55. Global Biosimilar Insulin Glargine Consumption Value by Type (2018-2023) & (USD Million)
    Table 56. Global Biosimilar Insulin Glargine Consumption Value by Type (2024-2029) & (USD Million)
    Table 57. Global Biosimilar Insulin Glargine Average Price by Type (2018-2023) & (US$/Unit)
    Table 58. Global Biosimilar Insulin Glargine Average Price by Type (2024-2029) & (US$/Unit)
    Table 59. Global Biosimilar Insulin Glargine Sales Quantity by Application (2018-2023) & (K Units)
    Table 60. Global Biosimilar Insulin Glargine Sales Quantity by Application (2024-2029) & (K Units)
    Table 61. Global Biosimilar Insulin Glargine Consumption Value by Application (2018-2023) & (USD Million)
    Table 62. Global Biosimilar Insulin Glargine Consumption Value by Application (2024-2029) & (USD Million)
    Table 63. Global Biosimilar Insulin Glargine Average Price by Application (2018-2023) & (US$/Unit)
    Table 64. Global Biosimilar Insulin Glargine Average Price by Application (2024-2029) & (US$/Unit)
    Table 65. North America Biosimilar Insulin Glargine Sales Quantity by Type (2018-2023) & (K Units)
    Table 66. North America Biosimilar Insulin Glargine Sales Quantity by Type (2024-2029) & (K Units)
    Table 67. North America Biosimilar Insulin Glargine Sales Quantity by Application (2018-2023) & (K Units)
    Table 68. North America Biosimilar Insulin Glargine Sales Quantity by Application (2024-2029) & (K Units)
    Table 69. North America Biosimilar Insulin Glargine Sales Quantity by Country (2018-2023) & (K Units)
    Table 70. North America Biosimilar Insulin Glargine Sales Quantity by Country (2024-2029) & (K Units)
    Table 71. North America Biosimilar Insulin Glargine Consumption Value by Country (2018-2023) & (USD Million)
    Table 72. North America Biosimilar Insulin Glargine Consumption Value by Country (2024-2029) & (USD Million)
    Table 73. Europe Biosimilar Insulin Glargine Sales Quantity by Type (2018-2023) & (K Units)
    Table 74. Europe Biosimilar Insulin Glargine Sales Quantity by Type (2024-2029) & (K Units)
    Table 75. Europe Biosimilar Insulin Glargine Sales Quantity by Application (2018-2023) & (K Units)
    Table 76. Europe Biosimilar Insulin Glargine Sales Quantity by Application (2024-2029) & (K Units)
    Table 77. Europe Biosimilar Insulin Glargine Sales Quantity by Country (2018-2023) & (K Units)
    Table 78. Europe Biosimilar Insulin Glargine Sales Quantity by Country (2024-2029) & (K Units)
    Table 79. Europe Biosimilar Insulin Glargine Consumption Value by Country (2018-2023) & (USD Million)
    Table 80. Europe Biosimilar Insulin Glargine Consumption Value by Country (2024-2029) & (USD Million)
    Table 81. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Type (2018-2023) & (K Units)
    Table 82. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Type (2024-2029) & (K Units)
    Table 83. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Application (2018-2023) & (K Units)
    Table 84. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Application (2024-2029) & (K Units)
    Table 85. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Region (2018-2023) & (K Units)
    Table 86. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity by Region (2024-2029) & (K Units)
    Table 87. Asia-Pacific Biosimilar Insulin Glargine Consumption Value by Region (2018-2023) & (USD Million)
    Table 88. Asia-Pacific Biosimilar Insulin Glargine Consumption Value by Region (2024-2029) & (USD Million)
    Table 89. South America Biosimilar Insulin Glargine Sales Quantity by Type (2018-2023) & (K Units)
    Table 90. South America Biosimilar Insulin Glargine Sales Quantity by Type (2024-2029) & (K Units)
    Table 91. South America Biosimilar Insulin Glargine Sales Quantity by Application (2018-2023) & (K Units)
    Table 92. South America Biosimilar Insulin Glargine Sales Quantity by Application (2024-2029) & (K Units)
    Table 93. South America Biosimilar Insulin Glargine Sales Quantity by Country (2018-2023) & (K Units)
    Table 94. South America Biosimilar Insulin Glargine Sales Quantity by Country (2024-2029) & (K Units)
    Table 95. South America Biosimilar Insulin Glargine Consumption Value by Country (2018-2023) & (USD Million)
    Table 96. South America Biosimilar Insulin Glargine Consumption Value by Country (2024-2029) & (USD Million)
    Table 97. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Type (2018-2023) & (K Units)
    Table 98. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Type (2024-2029) & (K Units)
    Table 99. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Application (2018-2023) & (K Units)
    Table 100. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Application (2024-2029) & (K Units)
    Table 101. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Region (2018-2023) & (K Units)
    Table 102. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity by Region (2024-2029) & (K Units)
    Table 103. Middle East & Africa Biosimilar Insulin Glargine Consumption Value by Region (2018-2023) & (USD Million)
    Table 104. Middle East & Africa Biosimilar Insulin Glargine Consumption Value by Region (2024-2029) & (USD Million)
    Table 105. Biosimilar Insulin Glargine Raw Material
    Table 106. Key Manufacturers of Biosimilar Insulin Glargine Raw Materials
    Table 107. Biosimilar Insulin Glargine Typical Distributors
    Table 108. Biosimilar Insulin Glargine Typical Customers
List of Figures
    Figure 1. Biosimilar Insulin Glargine Picture
    Figure 2. Global Biosimilar Insulin Glargine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Biosimilar Insulin Glargine Consumption Value Market Share by Type in 2022
    Figure 4. Pre-filled Examples
    Figure 5. Cartridge Examples
    Figure 6. Global Biosimilar Insulin Glargine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 7. Global Biosimilar Insulin Glargine Consumption Value Market Share by Application in 2022
    Figure 8. Hospital Examples
    Figure 9. Retail Pharmacy Examples
    Figure 10. Others Examples
    Figure 11. Global Biosimilar Insulin Glargine Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 12. Global Biosimilar Insulin Glargine Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 13. Global Biosimilar Insulin Glargine Sales Quantity (2018-2029) & (K Units)
    Figure 14. Global Biosimilar Insulin Glargine Average Price (2018-2029) & (US$/Unit)
    Figure 15. Global Biosimilar Insulin Glargine Sales Quantity Market Share by Manufacturer in 2022
    Figure 16. Global Biosimilar Insulin Glargine Consumption Value Market Share by Manufacturer in 2022
    Figure 17. Producer Shipments of Biosimilar Insulin Glargine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 18. Top 3 Biosimilar Insulin Glargine Manufacturer (Consumption Value) Market Share in 2022
    Figure 19. Top 6 Biosimilar Insulin Glargine Manufacturer (Consumption Value) Market Share in 2022
    Figure 20. Global Biosimilar Insulin Glargine Sales Quantity Market Share by Region (2018-2029)
    Figure 21. Global Biosimilar Insulin Glargine Consumption Value Market Share by Region (2018-2029)
    Figure 22. North America Biosimilar Insulin Glargine Consumption Value (2018-2029) & (USD Million)
    Figure 23. Europe Biosimilar Insulin Glargine Consumption Value (2018-2029) & (USD Million)
    Figure 24. Asia-Pacific Biosimilar Insulin Glargine Consumption Value (2018-2029) & (USD Million)
    Figure 25. South America Biosimilar Insulin Glargine Consumption Value (2018-2029) & (USD Million)
    Figure 26. Middle East & Africa Biosimilar Insulin Glargine Consumption Value (2018-2029) & (USD Million)
    Figure 27. Global Biosimilar Insulin Glargine Sales Quantity Market Share by Type (2018-2029)
    Figure 28. Global Biosimilar Insulin Glargine Consumption Value Market Share by Type (2018-2029)
    Figure 29. Global Biosimilar Insulin Glargine Average Price by Type (2018-2029) & (US$/Unit)
    Figure 30. Global Biosimilar Insulin Glargine Sales Quantity Market Share by Application (2018-2029)
    Figure 31. Global Biosimilar Insulin Glargine Consumption Value Market Share by Application (2018-2029)
    Figure 32. Global Biosimilar Insulin Glargine Average Price by Application (2018-2029) & (US$/Unit)
    Figure 33. North America Biosimilar Insulin Glargine Sales Quantity Market Share by Type (2018-2029)
    Figure 34. North America Biosimilar Insulin Glargine Sales Quantity Market Share by Application (2018-2029)
    Figure 35. North America Biosimilar Insulin Glargine Sales Quantity Market Share by Country (2018-2029)
    Figure 36. North America Biosimilar Insulin Glargine Consumption Value Market Share by Country (2018-2029)
    Figure 37. United States Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 38. Canada Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 39. Mexico Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 40. Europe Biosimilar Insulin Glargine Sales Quantity Market Share by Type (2018-2029)
    Figure 41. Europe Biosimilar Insulin Glargine Sales Quantity Market Share by Application (2018-2029)
    Figure 42. Europe Biosimilar Insulin Glargine Sales Quantity Market Share by Country (2018-2029)
    Figure 43. Europe Biosimilar Insulin Glargine Consumption Value Market Share by Country (2018-2029)
    Figure 44. Germany Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 45. France Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 46. United Kingdom Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 47. Russia Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 48. Italy Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity Market Share by Type (2018-2029)
    Figure 50. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity Market Share by Application (2018-2029)
    Figure 51. Asia-Pacific Biosimilar Insulin Glargine Sales Quantity Market Share by Region (2018-2029)
    Figure 52. Asia-Pacific Biosimilar Insulin Glargine Consumption Value Market Share by Region (2018-2029)
    Figure 53. China Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 54. Japan Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 55. Korea Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 56. India Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 57. Southeast Asia Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. Australia Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. South America Biosimilar Insulin Glargine Sales Quantity Market Share by Type (2018-2029)
    Figure 60. South America Biosimilar Insulin Glargine Sales Quantity Market Share by Application (2018-2029)
    Figure 61. South America Biosimilar Insulin Glargine Sales Quantity Market Share by Country (2018-2029)
    Figure 62. South America Biosimilar Insulin Glargine Consumption Value Market Share by Country (2018-2029)
    Figure 63. Brazil Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 64. Argentina Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 65. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity Market Share by Type (2018-2029)
    Figure 66. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity Market Share by Application (2018-2029)
    Figure 67. Middle East & Africa Biosimilar Insulin Glargine Sales Quantity Market Share by Region (2018-2029)
    Figure 68. Middle East & Africa Biosimilar Insulin Glargine Consumption Value Market Share by Region (2018-2029)
    Figure 69. Turkey Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 70. Egypt Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 71. Saudi Arabia Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 72. South Africa Biosimilar Insulin Glargine Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 73. Biosimilar Insulin Glargine Market Drivers
    Figure 74. Biosimilar Insulin Glargine Market Restraints
    Figure 75. Biosimilar Insulin Glargine Market Trends
    Figure 76. Porters Five Forces Analysis
    Figure 77. Manufacturing Cost Structure Analysis of Biosimilar Insulin Glargine in 2022
    Figure 78. Manufacturing Process Analysis of Biosimilar Insulin Glargine
    Figure 79. Biosimilar Insulin Glargine Industrial Chain
    Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 81. Direct Channel Pros & Cons
    Figure 82. Indirect Channel Pros & Cons
    Figure 83. Methodology
    Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Eli Lilly
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt

Related Reports

Global Biosimilar Insulin Glargine Supply, Demand and Key Producers, 2023-2029

Global Biosimilar Insulin Glargine Supply, Demand and Key Producers, 2023-2029

date 25 Feb 2023

date Pharma & Healthcare

The global Biosimilar Insulin Glargine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Biosimilar Insulin Glargine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Biosimilar Insulin Glargine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 09 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Biosimilar Insulin Glargine market size was valued at USD 2105.6 million in 2023 and is forecast to a readjusted size of USD 2533.8 million by 2030 with a CAGR of 2.7% during review period.

Global Biosimilar Insulin Glargine Supply, Demand and Key Producers, 2024-2030

Global Biosimilar Insulin Glargine Supply, Demand and Key Producers, 2024-2030

date 18 Feb 2024

date Pharma & Healthcare

The global Biosimilar Insulin Glargine market size is expected to reach $ 2533.8 million by 2030, rising at a market growth of 2.7% CAGR during the forecast period (2024-2030).

Product Tags

Biosimilar Insulin Glargine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>